Study Graphic

Study number: B7921028

You may be eligible if:

  • You are a healthy male or female 18-55 years of age.
  • You are able to meet all eligibility criteria.
  • You are able to comply with all study visits.

Be compensated for your time: $5150.00 for completion of the study

 The Pfizer New Haven Clinical Research Unit is conducting a study of new investigational drugs used to treat people with inflammatory conditions and diseases. This includes:

  • Alopecia areata (bald patches)
  • Vitiligo (loss of skin pigment)
  • Rheumatoid arthritis (RA)
  • Inflammatory bowel disease
    • Ulcerative colitis
    • Crohn’s disease

This study involves:

You will be in this study up to about 59 days. This does not include the time between screening and dosing, which can be up to 28 days.

  • 2 dosing periods (2 separate admissions)
  • 19 overnight stays
    • 6 nights for Period 1
    • 13 nights for Period 2
  • 1 follow-up phone call (between 28 and 35 days after the last dose of study drug)     

Please review the Informed Consent Document: B7921028 ICD v 24 Jan 2019

Please review more information about the study: B7921028 Guidelines and Restrictions